secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2021-11-17T23:59:59+00:00
Accession:  0001193125-21-331409
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio appoints Dr. Trishna Goswami as Chief Medical Officer
------------------------------------------------------------

- Annual base salary of $450,000; eligible for annual bonus targeted at 40% of base; signing bonus $10,000.
- Awarded option to purchase 250,000 shares vesting over 4 years (25% at year 1).
- Severance includes 12 months base salary, prorated target bonus, and 9 months COBRA if terminated without cause or for good reason.
- Dr. Goswami previously led Trodelvy approvals at Gilead/Immunomedics; also worked at Stemline and AstraZeneca/MedImmune.
- Appointment effective November 15, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312521331409/0001193125-21-331409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312521331409/d238625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-331409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer